1Cell.Ai is a precision-oncology platform that performs liquid biopsy and NGS-based cancer profiling, isolates viable circulating tumor cells for single-cell multi-omic analysis (DNA/RNA/protein), and delivers machine-learning-driven analytics and automated reporting to support therapy selection, longitudinal monitoring, and biomarker discovery.
Published Sep 19, 2026
| Starting Price | Not publicly listed (quote-based) | Patient-facing cash-pay guidance appears on some pages (historical patient guidance at a published cash-pay price) | Not presented as a simple public list price; coverage and financial support resources emphasized; jurisdictional list prices vary |
| Primary use cases | Programs that require viable CTC isolation plus multi-omic profiling and protein-target assessment; translational research and clinical trials | Widely adopted ctDNA liquid biopsy ecosystem with established coverage and access programs | Tissue and liquid comprehensive genomic profiling with extensive evidence and companion-diagnostic integration |
| Advantages | Vendor claims isolation of viable CTCs combined with single-cell and multi-omic analysis | Scale, payer engagement, and established clinical adoption | Established clinical footprint, approved assays, and payer relationships |
| Limitations | Limited third-party review coverage; limited public enterprise security attestations; pricing opacity | Costs can be substantial without coverage; payer variability in coverage policies | Tissue requirements can be a barrier for some patients; pricing and perceived cost are factors |
—